genzyme american biotechnology company based cambridge massachusetts since acquisition genzyme also known genzyme transgenics corp gtc fully owned subsidiary sanofi genzyme worlds thirdlargest biotechnology company employing people around world subsidiary sanofi genzyme presence approximately countries including manufacturing facilities genetictesting laboratories products also sold countries genzyme generated billion revenue products market genzyme named one fortune magazine best companies work company donated million worth products worldwide made million cash donations genzyme awarded national medal technology highest level honor awarded president united states americas leading february sanofis new corporate brand unveiled former entity sanofi genzyme got integrated company started sheridan snyder george whitesides genzymes scientific founder henry blair contract national institutes health nih produce modified enzymes nih test clinical blair technician new england enzyme center tufts medical genzymes first office old clothing warehouse adjacent tufts medical help venture capital funding company made first acquisition whatman biochemicals ltd made second acquisition britishbased kochlight laboratories later becoming genzyme pharmaceutical fine henri termeer joined genzyme president worked redirect company time reached valuation million focus diagnostic enzymes modified enzymes use human robin berman md volunteered nih threeyearold son brian gauchers disease scheduled spleen removal mother pleaded roscoe brady md expert gauchers disease include brian clinical trial ceredase along seven patients trial ultimately failed due use low dose enzyme ceredase went become companys important product line receiving fda approval termeer became companys chief executive officer ceo took company termeer acquired integrated genetics strengthening companys presence molecular biology protein chemistry carbohydrate engineering nucleic acid chemistry following approval success ceredase genzyme became devoted finding drugs involving recombinant human would treat enzyme deficiency conditions essential human survival usually afflict small percentage worlds population drugs used treat conditions considered orphan drugs ceredase first effective treatment gauchers disease previously rare untreatable potentially fatal genetic time ceredase also drew criticism expensive drug ever sold average per patient genzyme also took ig laboratories acquired public raising million ipo genzymes also sold interest genetrak systems million acquired genecore internationals diagnostic enzyme genzyme acquired medix biotech inc producer supplier monoclonal polyclonal antibodies immunoassay components immunodiagnostic services year genzyme limited acquired enzymatix ltd genetics testing laboratory company acquired german distributor invitro diagnostic kits virotech immunobiological products manufacturer omni res genzyme received fda approval market cerezyme genetically engineered replacement company acquired sygena ltd biosurface technology inc tsi inc tsi acquired genzyme transgenics corp percent owned genzyme company acquired pharmagenics inc creating genzyme molecular genzyme surgical products established within wider company announced plan acquire biomatrix august company acquired sangstat medical corp principal antiorgan rejection drug named thymoglobulin million company acquired ilex oncology genzyme acquired several impaths laboratories cancertesting technologies may impath sought chapter bankruptcy company acquired bone care international inc company acquired anormed inc company agreed acquire bioenvision million motivated potential leukemia treatment year companys acquisition sanofiaventis genzyme million net income revenue billion fourthlargest american biopharmaceutical time enzyme therapies accounted revenues portfolio managed personalized genetic health unit largest five operating year company sold genzyme genetics million sanofi acquired company following illustration companys major mergers acquisitions historical predecessors comprehensive list genzymefounded whatman biochemicals ltdacq kochlight laboratoriesacq integrated geneticsacq ipo genecore internationaldiagnostic enzyme div acq medix biotech incacq enzymatix ltdacq vivigenacq virotechacq omni res srlacq sygena ltdacq biosurface technology incacq tsi incacq pharmagenics incacq biomatrix acq geltex pharmaceuticalsacq sangstat medical corpacq ilex oncology incacq bone care international incacq anormed inc acq bioenvision acq genzyme focuses six areas medicine relating lysosomal storage diseases renal disease orthopedics transplant immune diseases oncology genetics diagnostics first orphandrug genzyme fda approved ceredase drug treating gaucher disease ceredase eventually replaced cerezyme cost per patient annually life currently accounts approximately genzymes revenue important drugs made genzyme renagel used treatment dialysis patients fabrazyme used treat patients fabrys disease products development tolevamer clostridium difficile colitis campath chronic lymphocytic leukemia genzyme sublicense bioenvision market clofarabine north america may genzyme made tender offer purchase bioenvision per share october majority shareholders voted approve genzymes ceo president board chairman henri termeer earned salary million noncash compensation worth genzyme launched kidney medication irish market waterford base set nine years manufacturing sites allston usa geel belgium framingham usa haverhill suffolk uk waterford munster ireland june genzymes allston massachusetts plant shut correct viral contamination vesivirus similar event occurred geel belgium facilities april restarted operation diminished november fragments stainless steel rubber fiberlike material discovered genzymes drugs fda found materials cerezyme genzymes treatment gaucher disease rare genetic disorder lead lifethreatening organ damage fda permitting drug stay market due lack adverse events critical need supplies fabrazyme genzymes treatment fabry disease rationed onethird recommended dose prompting patients file petition asking license produce fabrazyme manufacturers make deficit genzyme spent million lobbying alone different organizations total lobbyists working august sanofi announced bid acquire genzyme billion deal later rejected board genzyme february sanofi declared full acquisition genzyme september genzyme accepted responsibility agreed pay million us charges marketing adhesion barrier product seprafilm genzymes sales representatives instructing surgeons create slurry using seprafilm use laparoscopic surgeries use seprafilm genzyme also reached million civil agreement pertaining marketing seprafilm december genzyme claimed violation federal false claims httpsenwikipediaorgwikigenzyme